SYRE
Spyre Therapeutics Inc.
85.70$
+7.2%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 100.0% | – | – | – | – | – | – | – | 100.0% | – | – | 100.0% | |
| – | 92.5% | – | – | – | – | – | – | – | 50.0% | – | – | – | |
| – | 7.5% | – | – | – | – | – | – | – | 50.0% | – | – | – | |
| – | 3,232.4% | – | – | – | – | – | – | – | 49.3% | – | – | 238.5% | |
| – | 1,350.5% | – | – | – | – | – | – | – | 13.9% | – | – | 61.4% | |
| – | 4,406.3% | – | – | – | – | – | – | – | 113.2% | – | – | 222.5% | |
| – | -4,406.3% | – | – | – | – | – | – | – | -63.2% | – | – | -222.5% | |
| – | -6,063.3% | – | – | – | – | – | – | – | -69.1% | – | – | -197.7% | |
| – | -551.4% | – | – | – | – | – | – | – | 0.0% | – | – | – | |
| – | -6,063.3% | – | – | – | – | – | – | – | -69.1% | – | – | -197.7% | |
| – | -4,582.9% | – | – | – | – | – | – | – | -69.1% | – | – | -205.0% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.